SEC EDGARAUG 271 min read$THC

Sutaria Saumya sold $27.6M of THC

Sutaria Saumya (CEO) sold 100,000 shares of TENET HEALTHCARE CORP (THC) at an average of $276.36 ($273.34–$278.90, $27.64M total) across 5 trades over 2026-08-24 to 2026-08-25.

Original reporting

SEC EDGAR · Sutaria Saumya

Published Aug 27, 2026, 12:00 AM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 27, 2026, 12:13 AM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$THC

Bearish

medium confidence

Mentioned

$THC

Relevance

7/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$THCBearishLow

Why it matters

The CEO's $27.6M share sale may trigger short interest and price volatility.

Market read

First disclosure of a sizable insider sell; traders may reassess THC exposure.

What to watch

no 10b5‑1 plan, suggesting discretionary timing

Relevance 7/10Novelty 7/10Timing: filing disclosed on 2026‑08‑26 after market close

Background

Form 4 filing reports insider transaction for Tenet Healthcare Corp (THC).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$THCBearishMedium confidence

Context

CEO Sutaria Saumya sold 100,000 shares for $27.6M, reducing ownership to 433,564 shares.

Expected impact

potential short-term downside pressure

Evidence & confidence

CEO sale of $27M is material for a mid‑cap biotech; market may interpret as negative.

Market effects

Sector

may raise concerns for other biotech insiders and affect sector sentiment

Regional

limited to US biotech market

Global

low

Counterpoint

What could challenge this read

sale could be a routine liquidity event, not a confidence signal

Key entities

company
Tenet Healthcare Corp
Biotech firm listed on Nasdaq under ticker THC
person
Sutaria Saumya
CEO and director of Tenet Healthcare Corp

Read at source ← All news

AUG 23

$MDTMedAI 8/10

Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

yahoo.com3 min

AUG 18

$THCMedAI 8/10

Tenet Healthcare stock hits all-time high at 270.79 USD

Tenet Healthcare (THC) stock hit an all-time high of $270.79, up 54.4% over the past year. The company reported strong Q2 2026 earnings, exceeding expectations with $6.12 EPS on $5.63B revenue. Analysts raised price targets, with UBS setting the highest at $308. THC's P/E ratio is 10.46, and PEG ratio is 0.15, suggesting attractive valuation.

investing.com4 min

AUG 11

$THCMed

Tenet Healthcare’s (THC) Turnaround Is Working, but Can Its Growth Last?

Tenet Healthcare (NYSE:THC) reported fiscal Q2 2026 results that beat estimates and raised its full-year outlook. Adjusted EPS rose 52.2% to $6.12 and net operating revenue increased 6.8% to $5.63B. Hospital adjusted EBITDA margin expanded to 18.0%. Guidance: adjusted EBITDA $4.83B-$5.03B and net operating revenue $21.9B-$22.5B.

insidermonkey.com5 min

JUL 31

$HCAMed

Uninsured patients rise sharply, hospitals report, citing Obamacare cuts | Chattanooga Times Free Press

More and more uninsured patients are showing up in hospital emergency rooms and clinics, having lost their coverage under the Affordable Care Act. Executives running some of the biggest hospital systems, including large for-profit chains spanning many states, expressed concern over the unexpectedly sharp rise in uninsured patients and the costs associated with treating them.

timesfreepress.com7 min

JUL 28

$THCMedAI 8/10

Tenet raises 2026 outlook after weathering ACA headwinds

Tenet Healthcare raised 2026 guidance after Q2 headwinds on Affordable Care Act exchanges. The company now expects adjusted EBITDA of $4.8B to $5.0B, up from $4.5B to $4.8B. Q2 net income rose to $826M on $5.6B revenue, though ACA revenue fell $65M as ACA admissions declined.

yahoo.com4 min

JUL 27

$THCHighAI 9/10

Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook

Tenet Healthcare (THC) reported Q2 2026 adjusted EPS of $6.12, 50% above the Zacks Consensus, with net operating revenues up 6.8% to $5.63B. Adjusted net income rose 39.3% to $514M. The company raised 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and authorized a $2B share repurchase increase.

tradingview.com6 min